PERSPECTA

News from every angle

← Back to headlines

BTIG Sees Upside for ImmunityBio Amid Strong ANKTIVA Sales Growth

BTIG analysts are projecting an upside for ImmunityBio, Inc. (IBRX), attributing their positive outlook to strong anticipated sales growth for ANKTIVA in 2026.

PostShare

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

Yahoobcl21d ago

BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth

Read full article →

Related Stories

Oil Prices Rise After Previous Day's Sharp Drop

just now

Bank of Latvia Warns Abolishing Second Pension Pillar Requires Higher Labor Taxes

2h ago

IGIB ETF Offers Broader Bond Exposure Compared to FIGB

2h ago

Montenegrin Parliamentary Parties Spent Nearly €700,000 Last Year

2h ago